Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Cbp-dependent histone acetylation mediates axon regeneration induced by environmental enrichment in rodent spinal cord injury models.

Hutson TH, Kathe C, Palmisano I, Bartholdi K, Hervera A, De Virgiliis F, McLachlan E, Zhou L, Kong G, Barraud Q, Danzi MC, Medrano-Fernandez A, Lopez-Atalaya JP, Boutillier AL, Sinha SH, Singh AK, Chaturbedy P, Moon LDF, Kundu TK, Bixby JL, Lemmon VP, Barco A, Courtine G, Di Giovanni S.

Sci Transl Med. 2019 Apr 10;11(487). pii: eaaw2064. doi: 10.1126/scitranslmed.aaw2064.

PMID:
30971452
2.

Development and maintenance of the brain's immune toolkit: Microglia and non-parenchymal brain macrophages.

Lopez-Atalaya JP, Askew KE, Sierra A, Gomez-Nicola D.

Dev Neurobiol. 2018 Jun;78(6):561-579. doi: 10.1002/dneu.22545. Epub 2017 Oct 24. Review.

3.

Loss of Kdm5c Causes Spurious Transcription and Prevents the Fine-Tuning of Activity-Regulated Enhancers in Neurons.

Scandaglia M, Lopez-Atalaya JP, Medrano-Fernandez A, Lopez-Cascales MT, Del Blanco B, Lipinski M, Benito E, Olivares R, Iwase S, Shi Y, Barco A.

Cell Rep. 2017 Oct 3;21(1):47-59. doi: 10.1016/j.celrep.2017.09.014.

4.

Lack of IL-1R8 in neurons causes hyperactivation of IL-1 receptor pathway and induces MECP2-dependent synaptic defects.

Tomasoni R, Morini R, Lopez-Atalaya JP, Corradini I, Canzi A, Rasile M, Mantovani C, Pozzi D, Garlanda C, Mantovani A, Menna E, Barco A, Matteoli M.

Elife. 2017 Mar 28;6. pii: e21735. doi: 10.7554/eLife.21735.

5.

Specific promoter deacetylation of histone H3 is conserved across mouse models of Huntington's disease in the absence of bulk changes.

Guiretti D, Sempere A, Lopez-Atalaya JP, Ferrer-Montiel A, Barco A, Valor LM.

Neurobiol Dis. 2016 May;89:190-201. doi: 10.1016/j.nbd.2016.02.004. Epub 2016 Feb 3.

PMID:
26851501
6.

Brain size regulations by cbp haploinsufficiency evaluated by in-vivo MRI based volumetry.

Ateca-Cabarga JC, Cosa A, Pallarés V, López-Atalaya JP, Barco Á, Canals S, Moratal D.

Sci Rep. 2015 Nov 6;5:16256. doi: 10.1038/srep16256.

7.

Blocking miRNA Biogenesis in Adult Forebrain Neurons Enhances Seizure Susceptibility, Fear Memory, and Food Intake by Increasing Neuronal Responsiveness.

Fiorenza A, Lopez-Atalaya JP, Rovira V, Scandaglia M, Geijo-Barrientos E, Barco A.

Cereb Cortex. 2016 Apr;26(4):1619-1633. doi: 10.1093/cercor/bhu332. Epub 2015 Jan 16.

PMID:
25595182
8.

Epigenetic factors in intellectual disability: the Rubinstein-Taybi syndrome as a paradigm of neurodevelopmental disorder with epigenetic origin.

Lopez-Atalaya JP, Valor LM, Barco A.

Prog Mol Biol Transl Sci. 2014;128:139-76. doi: 10.1016/B978-0-12-800977-2.00006-1. Review.

PMID:
25410544
9.

Can changes in histone acetylation contribute to memory formation?

Lopez-Atalaya JP, Barco A.

Trends Genet. 2014 Dec;30(12):529-39. doi: 10.1016/j.tig.2014.09.003. Epub 2014 Sep 27. Review.

PMID:
25269450
10.

Loss of neuronal 3D chromatin organization causes transcriptional and behavioural deficits related to serotonergic dysfunction.

Ito S, Magalska A, Alcaraz-Iborra M, Lopez-Atalaya JP, Rovira V, Contreras-Moreira B, Lipinski M, Olivares R, Martinez-Hernandez J, Ruszczycki B, Lujan R, Geijo-Barrientos E, Wilczynski GM, Barco A.

Nat Commun. 2014 Jul 18;5:4450. doi: 10.1038/ncomms5450.

PMID:
25034090
11.

Histone H3 lysine methylation in cognition and intellectual disability disorders.

Parkel S, Lopez-Atalaya JP, Barco A.

Learn Mem. 2013 Sep 17;20(10):570-9. doi: 10.1101/lm.029363.112. Review.

PMID:
24045506
12.

Genomic targets, and histone acetylation and gene expression profiling of neural HDAC inhibition.

Lopez-Atalaya JP, Ito S, Valor LM, Benito E, Barco A.

Nucleic Acids Res. 2013 Sep;41(17):8072-84. doi: 10.1093/nar/gkt590. Epub 2013 Jul 1.

13.

Genomic landscape of transcriptional and epigenetic dysregulation in early onset polyglutamine disease.

Valor LM, Guiretti D, Lopez-Atalaya JP, Barco A.

J Neurosci. 2013 Jun 19;33(25):10471-82. doi: 10.1523/JNEUROSCI.0670-13.2013.

14.

Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders.

Valor LM, Viosca J, Lopez-Atalaya JP, Barco A.

Curr Pharm Des. 2013;19(28):5051-64. Review.

15.

Histone acetylation deficits in lymphoblastoid cell lines from patients with Rubinstein-Taybi syndrome.

Lopez-Atalaya JP, Gervasini C, Mottadelli F, Spena S, Piccione M, Scarano G, Selicorni A, Barco A, Larizza L.

J Med Genet. 2012 Jan;49(1):66-74. doi: 10.1136/jmedgenet-2011-100354. Epub 2011 Oct 7.

16.

CBP is required for environmental enrichment-induced neurogenesis and cognitive enhancement.

Lopez-Atalaya JP, Ciccarelli A, Viosca J, Valor LM, Jimenez-Minchan M, Canals S, Giustetto M, Barco A.

EMBO J. 2011 Aug 16;30(20):4287-98. doi: 10.1038/emboj.2011.299.

17.

Syndromic features and mild cognitive impairment in mice with genetic reduction on p300 activity: Differential contribution of p300 and CBP to Rubinstein-Taybi syndrome etiology.

Viosca J, Lopez-Atalaya JP, Olivares R, Eckner R, Barco A.

Neurobiol Dis. 2010 Jan;37(1):186-94. doi: 10.1016/j.nbd.2009.10.001. Epub 2009 Oct 12.

PMID:
19822209
18.

Selective boosting of transcriptional and behavioral responses to drugs of abuse by histone deacetylase inhibition.

Sanchis-Segura C, Lopez-Atalaya JP, Barco A.

Neuropsychopharmacology. 2009 Dec;34(13):2642-54. doi: 10.1038/npp.2009.125. Epub 2009 Sep 2.

19.

Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity.

Lopez-Atalaya JP, Roussel BD, Levrat D, Parcq J, Nicole O, Hommet Y, Benchenane K, Castel H, Leprince J, To Van D, Bureau R, Rault S, Vaudry H, Petersen KU, Santos JS, Ali C, Vivien D.

J Cereb Blood Flow Metab. 2008 Jun;28(6):1212-21. doi: 10.1038/jcbfm.2008.14. Epub 2008 Mar 12.

PMID:
18334994
20.

Hunting for synaptic tagging and capture in memory formation.

Viosca J, Jancic D, López-Atalaya JP, Benito E.

J Neurosci. 2007 Nov 21;27(47):12761-3. Review. No abstract available.

21.

Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects.

López-Atalaya JP, Roussel BD, Ali C, Maubert E, Petersen KU, Berezowski V, Cecchelli R, Orset C, Vivien D.

Stroke. 2007 Mar;38(3):1036-43.

PMID:
17325305
22.

Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory.

Benchenane K, Castel H, Boulouard M, Bluthé R, Fernandez-Monreal M, Roussel BD, Lopez-Atalaya JP, Butt-Gueulle S, Agin V, Maubert E, Dantzer R, Touzani O, Dauphin F, Vivien D, Ali C.

J Cell Sci. 2007 Feb 15;120(Pt 4):578-85. Epub 2007 Jan 23.

23.

Tissue-type plasminogen activator rescues neurones from serum deprivation-induced apoptosis through a mechanism independent of its proteolytic activity.

Liot G, Roussel BD, Lebeurrier N, Benchenane K, López-Atalaya JP, Vivien D, Ali C.

J Neurochem. 2006 Sep;98(5):1458-64. Epub 2006 Jun 27.

24.

The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo.

Lebeurrier N, Liot G, Lopez-Atalaya JP, Orset C, Fernandez-Monreal M, Sonderegger P, Ali C, Vivien D.

Mol Cell Neurosci. 2005 Dec;30(4):552-8. Epub 2005 Oct 4.

PMID:
16209928
25.

Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis.

Benchenane K, Berezowski V, Ali C, Fernández-Monreal M, López-Atalaya JP, Brillault J, Chuquet J, Nouvelot A, MacKenzie ET, Bu G, Cecchelli R, Touzani O, Vivien D.

Circulation. 2005 May 3;111(17):2241-9. Epub 2005 Apr 25.

PMID:
15851587
26.

2,7-Bis-(4-amidinobenzylidene)-cycloheptan-1-one dihydrochloride, tPA stop, prevents tPA-enhanced excitotoxicity both in vitro and in vivo.

Liot G, Benchenane K, Léveillé F, López-Atalaya JP, Fernández-Monreal M, Ruocco A, Mackenzie ET, Buisson A, Ali C, Vivien D.

J Cereb Blood Flow Metab. 2004 Oct;24(10):1153-9.

PMID:
15529015
27.

Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling.

Fernández-Monreal M, López-Atalaya JP, Benchenane K, Cacquevel M, Dulin F, Le Caer JP, Rossier J, Jarrige AC, Mackenzie ET, Colloc'h N, Ali C, Vivien D.

J Biol Chem. 2004 Dec 3;279(49):50850-6. Epub 2004 Sep 23.

28.

Is tissue-type plasminogen activator a neuromodulator?

Fernández-Monreal M, López-Atalaya JP, Benchenane K, Léveillé F, Cacquevel M, Plawinski L, MacKenzie ET, Bu G, Buisson A, Vivien D.

Mol Cell Neurosci. 2004 Apr;25(4):594-601.

PMID:
15080889
29.

Equivocal roles of tissue-type plasminogen activator in stroke-induced injury.

Benchenane K, López-Atalaya JP, Fernández-Monreal M, Touzani O, Vivien D.

Trends Neurosci. 2004 Mar;27(3):155-60. Review.

PMID:
15036881

Supplemental Content

Loading ...
Support Center